MART-1 (26-35) human

MART-1 (26-35) human is a synthetic peptide fragment derived from the melanoma antigen recognized by T cells 1 (MART-1), specifically encompassing amino acids 26 to 35 of the human protein sequence. As a well-characterized epitope, this peptide is frequently utilized in immunological research to investigate antigen processing, presentation, and T cell recognition associated with melanoma. Its defined sequence enables precise experimental manipulation, making it a valuable reagent for dissecting cellular immune responses, especially in the context of tumor immunology and antigen-specific T cell activation.

Epitope mapping: Researchers employ the MART-1 (26-35) peptide to map T cell epitopes and characterize the antigenic determinants recognized by cytotoxic T lymphocytes (CTLs) in melanoma. By exposing immune cells to the peptide in vitro, investigators can delineate the specificity and breadth of T cell responses, facilitating a deeper understanding of immune recognition mechanisms and the identification of immunodominant regions within tumor-associated antigens.

Antigen presentation studies: The peptide is instrumental in studies examining the presentation of peptide antigens by major histocompatibility complex (MHC) class I molecules. By pulsing antigen-presenting cells such as dendritic cells or other professional APCs with MART-1 (26-35), researchers can evaluate the efficiency of peptide loading, surface expression of peptide-MHC complexes, and subsequent activation of MART-1-specific CD8+ T cells. These assays are essential for elucidating the molecular interactions underpinning adaptive immune surveillance in cancer.

T cell activation assays: In functional immunological assays, MART-1 (26-35) serves as a model antigen for stimulating and expanding antigen-specific T cell populations from peripheral blood mononuclear cells (PBMCs) or tumor-infiltrating lymphocytes (TILs). Its use enables detailed analysis of T cell effector functions, cytokine secretion profiles, and cytolytic activity, thereby supporting the development and optimization of immunotherapeutic strategies targeting tumor antigens.

Vaccine development research: The peptide is frequently incorporated into preclinical studies aimed at designing and evaluating peptide-based cancer vaccines. By assessing the immunogenicity and T cell response elicited by MART-1 (26-35), scientists can optimize vaccine formulations, delivery methods, and adjuvant combinations for enhanced induction of tumor-specific immunity. Such investigations are critical for advancing translational research in tumor antigen targeting and immunoprophylaxis.

Quality control and assay validation: Laboratories utilize MART-1 (26-35) as a positive control in a variety of immunological assays, including ELISPOT, intracellular cytokine staining, and flow cytometry-based detection of antigen-specific T cells. Its defined sequence and well-established immunogenic properties make it an ideal standard for validating experimental protocols, calibrating assay sensitivity, and ensuring reproducibility across immunomonitoring studies. By serving as a benchmark reagent, the peptide underpins robust quality assurance in immune response analysis.

1. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate

2. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

4. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs

5. Exosomes-mediated Transfer of miR-125a/b in Cell-to-cell Communication: A Novel Mechanism of Genetic Exchange in the Intestinal Microenvironment